Muramyldipeptide

Muramyldipeptide

SCHEMBL41814

CC(=O)N[C@@H]1[C@@H](O[C@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)O)C(N)=O)[C@H](O)[C@@H](CO)O[C@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOD2 Q9HC29 1/20 1.00
ESR1 P03372 2/20 0.68
PGR P06401 2/20 0.68
HTR1A P08908 1/20 0.68
ADORA3 P0DMS8 1/20 0.68
AR P10275 1/20 0.68
CHRM1 P11229 1/20 0.68
TBXA2R P21731 1/20 0.68
PTGS1 P23219 1/20 0.68
ADRA1A P35348 1/20 0.68
KCNH2 Q12809 1/20 0.68
MAPK1 P28482 1/20 0.60
ALDH1A1 P00352 1/20 0.40
THRB P10828 1/20 0.40
LGALS3 P17931 1/20 0.35
SELP P16109 5/20 0.34
SELL P14151 3/20 0.34
SELE P16581 3/20 0.34
ANPEP P15144 2/20 0.33
PTPN1 P18031 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Muramyldipeptide SCHEMBL20516503 1.00 NOD2 (1.00) NOD2ESR1PGRHTR1AADORA3
Muramyl Dipeptide SCHEMBL9770111 1.00 NOD2 (1.00) NOD2ESR1PGRHTR1AADORA3
Muramyldipeptide SCHEMBL15263102 1.00 NOD2 (1.00) NOD2ESR1PGRHTR1AADORA3
Muramyl Dipeptide SCHEMBL41813 1.00 NOD2 (1.00) NOD2ESR1PGRHTR1AADORA3
Muramyldipeptide SCHEMBL19486934 1.00 NOD2 (1.00) NOD2ESR1PGRHTR1AADORA3
Muramyldipeptide SCHEMBL20516502 1.00 NOD2 (1.00) NOD2ESR1PGRHTR1AADORA3
Muramyldipeptide SCHEMBL9231355 1.00 NOD2 (1.00) NOD2ESR1PGRHTR1AADORA3
Muramyldipeptide SCHEMBL17299289 1.00 NOD2 (1.00) NOD2ESR1PGRHTR1AADORA3
Muramyl Dipeptide SCHEMBL769016 0.99 NOD2 (0.98) NOD2ESR1PGRHTR1AADORA3
SCHEMBL16802190 0.94 NOD2 (0.88) NOD2ESR1PGRHTR1AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 23740 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122075695-A Application of CYLD as marker in preparation of intervention product for early-birth infant late-onset sepsis 2026-05-26 CN claimed
CN-122031666-A Application of recombinant DL-endopeptidase and metabolite thereof in preparation of medicine for preventing premature infant late-onset septicemia 南方医科大学珠江医院 2026-05-15 CN claimed
US-20260115281-A1 TRITERPENE SAPONIN ANALOGUES ADJUVANCE TECH INC (US) 2026-04-30 US claimed
US-12611448-B2 Targeting delivery system loaded with whole-cell components and use thereof Suzhou Ersheng Biopharmaceutical Co., Ltd (CN) 2026-04-28 US claimed
US-12611452-B2 Foot-and-mouth disease virus-like particle antigen, vaccine composition, preparation method, and use thereof PULIKE BIOLOGICAL ENGINEERING INC. (CN) 2026-04-28 US claimed
US-20260108454-A1 Innate Targeting of Adoptive Cellular Therapies QU BIOLOGICS INC (CA) 2026-04-23 US claimed
EP-4713015-A1 SURFACE DISPLAY OF IMMUNOTHERAPEUTICS ON EXTRACELLULAR VESICLES AND USES THEREOF National University of Singapore (SG) 2026-03-25 EP claimed
US-12582711-B2 RNA-based adjuvant to enhance the immune response to vaccines and therapeutics ImmuneSure LLC (US) 2026-03-24 US claimed
US-20260069672-A1 Porcine Circovirus Type 3 (PCV3) Vaccines, and Production and Uses Thereof BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2026-03-12 US claimed
US-12551545-B2 African swine fever virus chimeric protein, vaccine composition, preparation method and use thereof PULIKE BIOLOGICAL ENGINEERING INC (CN) 2026-02-17 US claimed
EP-0276278-A1 CHIMERIC PEPTIDES FOR NEUROPEPTIDE DELIVERY THROUGH THE BLOOD-BRAIN BARRIER. UNIV CALIFORNIA (US) 1988-08-03 EP claimed
WO-1988000834-A1 CHIMERIC PEPTIDES FOR NEUROPEPTIDE DELIVERY THROUGH THE BLOOD-BRAIN BARRIER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1988-02-11 WO claimed
US-4711842-A FUSING MACROPHAGE TUMOR CELL LINE WITH NON-TUMOR MACROPHAGE; INTERLEUKIN-1 PRODUCED ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1987-12-08 US claimed
US-4652449-A Encapsulating biological active substances into erythrocytes CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1987-03-24 US claimed
EP-0192671-A4 MINACTIVIN. BIOTECH AUSTRALIA PTY LTD (AU) 1987-01-22 EP claimed
EP-0192671-A1 MINACTIVIN. BIOTECH AUSTRALIA PTY LTD (AU) 1986-09-03 EP claimed
EP-0179791-A1 A PHARMACEUTICAL PRODUCT HAVING AN ANTI-TUMOR ACTIVITY; THE USE OF A PHARMACEUTICAL PRODUCT OR OF PHARMACEUTICAL COMPOSITIONS IN AN ANTI-TUMOR THERAPY Rijksuniversiteit Utrecht (NL) 1986-05-07 EP claimed
WO-1986001212-A1 MINACTIVIN BIOTECHNOLOGY AUSTRALIA PTY. LTD. (AU) 1986-02-27 WO claimed
WO-1985004807-A1 A PHARMACEUTICAL PRODUCT HAVING AN ANTI-TUMOR ACTIVITY; THE USE OF A PHARMACEUTICAL PRODUCT OR OF PHARMACEUTICAL COMPOSITIONS IN AN ANTI-TUMOR THERAPY RIJKSUNIVERSITEIT UTRECHT (NL) 1985-11-07 WO claimed
EP-0094997-A1 Bovine mastitis vaccine, process for preparing it, and method for detecting efficacy thereof CORNELL RESEARCH FOUNDATION, INC. (US) 1983-11-30 EP claimed